145 related articles for article (PubMed ID: 37925022)
1. Spatiotemporal regulation of GIPR signaling impacts glucose homeostasis as revealed in studies of a common GIPR variant.
Yammine L; Picatoste B; Abdullah N; Leahey RA; Johnson EF; Gómez-Banoy N; Rosselot C; Wen J; Hossain T; Goncalves MD; Lo JC; Garcia-Ocaña A; McGraw TE
Mol Metab; 2023 Dec; 78():101831. PubMed ID: 37925022
[TBL] [Abstract][Full Text] [Related]
2. Genetically Predicted Glucose-Dependent Insulinotropic Polypeptide (GIP) Levels and Cardiovascular Disease Risk Are Driven by Distinct Causal Variants in the
Bowker N; Hansford R; Burgess S; Foley CN; Auyeung VPW; Erzurumluoglu AM; Stewart ID; Wheeler E; Pietzner M; Gribble F; Reimann F; Bhatnagar P; Coghlan MP; Wareham NJ; Langenberg C
Diabetes; 2021 Nov; 70(11):2706-2719. PubMed ID: 34426508
[TBL] [Abstract][Full Text] [Related]
3. Pleiotropic effects of GIP on islet function involve osteopontin.
Lyssenko V; Eliasson L; Kotova O; Pilgaard K; Wierup N; Salehi A; Wendt A; Jonsson A; De Marinis YZ; Berglund LM; Taneera J; Balhuizen A; Hansson O; Osmark P; Dunér P; Brøns C; Stancáková A; Kuusisto J; Bugliani M; Saxena R; Ahlqvist E; Kieffer TJ; Tuomi T; Isomaa B; Melander O; Sonestedt E; Orho-Melander M; Nilsson P; Bonetti S; Bonadonna R; Miccoli R; Delprato S; Marchetti P; Madsbad S; Poulsen P; Vaag A; Laakso M; Gomez MF; Groop L
Diabetes; 2011 Sep; 60(9):2424-33. PubMed ID: 21810601
[TBL] [Abstract][Full Text] [Related]
4. A novel GIP receptor splice variant influences GIP sensitivity of pancreatic beta-cells in obese mice.
Harada N; Yamada Y; Tsukiyama K; Yamada C; Nakamura Y; Mukai E; Hamasaki A; Liu X; Toyoda K; Seino Y; Inagaki N
Am J Physiol Endocrinol Metab; 2008 Jan; 294(1):E61-8. PubMed ID: 17971513
[TBL] [Abstract][Full Text] [Related]
5. Evaluation of a rare glucose-dependent insulinotropic polypeptide receptor variant in a patient with diabetes.
Jacobi SF; Khajavi N; Kleinau G; Teumer A; Scheerer P; Homuth G; Völzke H; Wiegand S; Kühnen P; Krude H; Gong M; Raile K; Biebermann H
Diabetes Obes Metab; 2019 May; 21(5):1168-1176. PubMed ID: 30784161
[TBL] [Abstract][Full Text] [Related]
6. A naturally occurring GIP receptor variant undergoes enhanced agonist-induced desensitization, which impairs GIP control of adipose insulin sensitivity.
Mohammad S; Patel RT; Bruno J; Panhwar MS; Wen J; McGraw TE
Mol Cell Biol; 2014 Oct; 34(19):3618-29. PubMed ID: 25047836
[TBL] [Abstract][Full Text] [Related]
7. Downregulation of a GPCR by β-Arrestin2-Mediated Switch from an Endosomal to a TGN Recycling Pathway.
Abdullah N; Beg M; Soares D; Dittman JS; McGraw TE
Cell Rep; 2016 Dec; 17(11):2966-2978. PubMed ID: 27974210
[TBL] [Abstract][Full Text] [Related]
8. The role of GIP in α-cells and glucagon secretion.
El K; Campbell JE
Peptides; 2020 Mar; 125():170213. PubMed ID: 31785304
[TBL] [Abstract][Full Text] [Related]
9. The pathogenic role of the GIP/GIPR axis in human endocrine tumors: emerging clinical mechanisms beyond diabetes.
Regazzo D; Barbot M; Scaroni C; Albiger N; Occhi G
Rev Endocr Metab Disord; 2020 Mar; 21(1):165-183. PubMed ID: 31933128
[TBL] [Abstract][Full Text] [Related]
10. Targeting the GIPR for obesity: To agonize or antagonize? Potential mechanisms.
Campbell JE
Mol Metab; 2021 Apr; 46():101139. PubMed ID: 33290902
[TBL] [Abstract][Full Text] [Related]
11. TCF1 links GIPR signaling to the control of beta cell function and survival.
Campbell JE; Ussher JR; Mulvihill EE; Kolic J; Baggio LL; Cao X; Liu Y; Lamont BJ; Morii T; Streutker CJ; Tamarina N; Philipson LH; Wrana JL; MacDonald PE; Drucker DJ
Nat Med; 2016 Jan; 22(1):84-90. PubMed ID: 26642437
[TBL] [Abstract][Full Text] [Related]
12. Discovery of a potent GIPR peptide antagonist that is effective in rodent and human systems.
Yang B; Gelfanov VM; El K; Chen A; Rohlfs R; DuBois B; Kruse Hansen AM; Perez-Tilve D; Knerr PJ; D'Alessio D; Campbell JE; Douros JD; Finan B
Mol Metab; 2022 Dec; 66():101638. PubMed ID: 36400403
[TBL] [Abstract][Full Text] [Related]
13. Disruption of GIP/GIPR axis in human adipose tissue is linked to obesity and insulin resistance.
Ceperuelo-Mallafré V; Duran X; Pachón G; Roche K; Garrido-Sánchez L; Vilarrasa N; Tinahones FJ; Vicente V; Pujol J; Vendrell J; Fernández-Veledo S
J Clin Endocrinol Metab; 2014 May; 99(5):E908-19. PubMed ID: 24512489
[TBL] [Abstract][Full Text] [Related]
14. Differential importance of glucose-dependent insulinotropic polypeptide vs glucagon-like peptide 1 receptor signaling for beta cell survival in mice.
Maida A; Hansotia T; Longuet C; Seino Y; Drucker DJ
Gastroenterology; 2009 Dec; 137(6):2146-57. PubMed ID: 19766644
[TBL] [Abstract][Full Text] [Related]
15. Glucose-dependent insulinotropic polypeptide receptor null mice exhibit compensatory changes in the enteroinsular axis.
Pamir N; Lynn FC; Buchan AM; Ehses J; Hinke SA; Pospisilik JA; Miyawaki K; Yamada Y; Seino Y; McIntosh CH; Pederson RA
Am J Physiol Endocrinol Metab; 2003 May; 284(5):E931-9. PubMed ID: 12540373
[TBL] [Abstract][Full Text] [Related]
16. Glucose-dependent insulinotropic polypeptide (GIP) receptor antagonists as anti-diabetic agents.
Gasbjerg LS; Gabe MBN; Hartmann B; Christensen MB; Knop FK; Holst JJ; Rosenkilde MM
Peptides; 2018 Feb; 100():173-181. PubMed ID: 29412817
[TBL] [Abstract][Full Text] [Related]
17. Human epicardial adipose tissue expresses glucose-dependent insulinotropic polypeptide, glucagon, and glucagon-like peptide-1 receptors as potential targets of pleiotropic therapies.
Malavazos AE; Iacobellis G; Dozio E; Basilico S; Di Vincenzo A; Dubini C; Menicanti L; Vianello E; Meregalli C; Ruocco C; Ragni M; Secchi F; Spagnolo P; Castelvecchio S; Morricone L; Buscemi S; Giordano A; Goldberger JJ; Carruba M; Cinti S; Corsi Romanelli MM; Nisoli E
Eur J Prev Cardiol; 2023 Jun; 30(8):680-693. PubMed ID: 36799940
[TBL] [Abstract][Full Text] [Related]
18. GIP mediates the incretin effect and glucose tolerance by dual actions on α cells and β cells.
El K; Gray SM; Capozzi ME; Knuth ER; Jin E; Svendsen B; Clifford A; Brown JL; Encisco SE; Chazotte BM; Sloop KW; Nunez DJ; Merrins MJ; D'Alessio DA; Campbell JE
Sci Adv; 2021 Mar; 7(11):. PubMed ID: 33712466
[TBL] [Abstract][Full Text] [Related]
19. Glucose-dependent Insulinotropic Polypeptide (GIP): From prohormone to actions in endocrine pancreas and adipose tissue.
Ugleholdt R
Dan Med Bull; 2011 Dec; 58(12):B4368. PubMed ID: 22142579
[TBL] [Abstract][Full Text] [Related]
20. Structural and pharmacological characterization of novel potent and selective monoclonal antibody antagonists of glucose-dependent insulinotropic polypeptide receptor.
Ravn P; Madhurantakam C; Kunze S; Matthews E; Priest C; O'Brien S; Collinson A; Papworth M; Fritsch-Fredin M; Jermutus L; Benthem L; Gruetter M; Jackson RH
J Biol Chem; 2013 Jul; 288(27):19760-72. PubMed ID: 23689510
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
